Solid Biosciences Inc. Common Stock
$8.61
$0.24 (+2.81%)
$8.27Day Range$8.69
Key Statistics
Market Cap
$897.48M
Shares Outstanding
107.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jan 25, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$8.62
Day High
$8.69
Day Low
$8.27
Volume
1.25M
VWAP
$8.48
Prev Close
$8.37
Transactions
--
Acc. Volume
--
About Solid Biosciences Inc. Common Stock
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836121 employees500 RUTHERFORD AVENUE, CHARLESTOWN, MA, 02129617-337-4680IPO Jan 25, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001707502
- Composite FIGI
- BBG00JN4FXG8
- Share Class FIGI
- BBG00JN4FXH7
- Ticker Root
- SLDB
- SIC Code
- 2836
About Solid Biosciences Inc. Common Stock (SLDB) Stock
Solid Biosciences Inc. Common Stock (SLDB) closed the 2026-09-16 session at $8.61, up 2.81% versus the previous close (+0.24). The stock opened at $8.62 and traded between $8.27 and $8.69 during that session. Session trading volume was 1.3M shares. The volume-weighted average price (VWAP) is $8.48.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Solid Biosciences Inc. Common Stock has a market capitalization of $897.5 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. SLDB is listed on the XNAS exchange. The company employs approximately 121 people. Solid Biosciences Inc. Common Stock is headquartered in CHARLESTOWN, MA. The recorded listing date is 2018-01-25.
On this page you can find market SLDB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.